HC Wainwright assumed coverage on shares of Benitec Biopharma (NASDAQ:BNTC - Free Report) in a research note published on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $28.00 target price on the biotechnology company's stock.
BNTC has been the subject of several other research reports. Guggenheim reiterated a "buy" rating and set a $17.00 target price on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Oppenheimer began coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They set an "outperform" rating and a $35.00 price objective for the company. Piper Sandler reissued an "overweight" rating on shares of Benitec Biopharma in a report on Friday, October 18th. Robert W. Baird started coverage on shares of Benitec Biopharma in a research report on Friday. They issued an "outperform" rating and a $30.00 price objective on the stock. Finally, JMP Securities boosted their price target on Benitec Biopharma from $16.00 to $18.00 and gave the stock a "market outperform" rating in a research report on Monday, October 14th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Benitec Biopharma presently has a consensus rating of "Buy" and a consensus target price of $24.43.
Read Our Latest Research Report on BNTC
Benitec Biopharma Price Performance
Shares of NASDAQ BNTC traded up $0.81 during trading on Monday, reaching $12.58. The stock had a trading volume of 66,123 shares, compared to its average volume of 46,096. Benitec Biopharma has a one year low of $2.69 and a one year high of $13.22. The firm's 50 day moving average price is $10.55 and its two-hundred day moving average price is $9.29.
Insider Activity
In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 42,000 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average price of $9.60 per share, with a total value of $403,200.00. Following the purchase, the director now directly owns 7,957,365 shares of the company's stock, valued at approximately $76,390,704. This trade represents a 0.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.30% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC acquired a new stake in shares of Benitec Biopharma during the 2nd quarter valued at $5,881,000. Simplify Asset Management Inc. raised its position in shares of Benitec Biopharma by 127.5% during the third quarter. Simplify Asset Management Inc. now owns 116,535 shares of the biotechnology company's stock worth $1,071,000 after purchasing an additional 65,319 shares during the period. Suvretta Capital Management LLC lifted its holdings in shares of Benitec Biopharma by 422.0% during the third quarter. Suvretta Capital Management LLC now owns 8,829,053 shares of the biotechnology company's stock valued at $81,139,000 after purchasing an additional 7,137,763 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Benitec Biopharma by 20.3% in the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 1,102 shares during the period. Finally, Acuta Capital Partners LLC purchased a new position in Benitec Biopharma in the 3rd quarter worth about $274,000. Institutional investors and hedge funds own 52.19% of the company's stock.
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
See Also
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
